Legal

Last Updated: February 17, 2025

We utilize a standardized terminology system designed to improve clarity and engagement in discussions surrounding BAT Levels and their role in Alzheimer’s Disease (AD).

Why the Terminology Matters:

• Many individuals perceive Alzheimer’s as an irreversible and untreatable disease, often causing fear and reluctance to seek early testing.

• By adopting a clear, structured, and approachable terminology, we aim to make cognitive health management more accessible and less intimidating while ensuring that both patients and providers understand the importance of early detection and intervention.

• The BATWatch Protocol establishes standardized language for the various components of Alzheimer’s biomarker testing, monitoring, and treatment. This section outlines the key terms used throughout this document and our protocol.

2.1 BATWatch

Definition: BATWatch is a structured cognitive health monitoring and intervention system designed to track BAT Levels, guide interventions, and optimize long-term brain health.

Purpose:
• Provides a standardized system for monitoring biomarker trends over time.
• Integrates diagnostic testing and intervention strategies for comprehensive cognitive health management.
• Reduces patient fear and misinformation through a clear, structured, and proactive approach to Alzheimer’s prevention.

2.2 BATWatch Protocol

Definition: The BATWatch Protocol is a structured, multi-phase framework for cognitive health management, including:

• Early detection of BAT Levels.
• Risk stratification based on the BAT Mechanism Panel results.
• Implementation of personalized intervention strategies (BAT Pill Protocol).
• Longitudinal tracking of biomarker progression.

Key Features:

• Test-Agnostic Approach: Designed to integrate multiple validated biomarker tests to maximize diagnostic accuracy.
• Multiple-Testing Methodology: Reduces false positives and false negatives to ensure over 90% cumulative accuracy, even when using standalone tests with lower sensitivity.
• Comprehensive & Flexible: Adapts to emerging diagnostic innovations while maintaining a structured framework for clinical implementation.

2.3 BAT Levels

Definition: BAT Levels refer to the quantified measurement of Beta-Amyloid and Tau proteins in the blood as biomarkers for Alzheimer’s risk.

Purpose:
• Provides a consistent, structured classification for monitoring Alzheimer’s-related biomarkers.
• Enables longitudinal tracking of biomarker fluctuations to assess cognitive health trends.
• Bridges the communication gap between patients and medical professionals.

2.4 BAT Level Index (BLI)

Definition: The BAT Level Index (BLI) is a cognitive health scoring system that uses a proprietary algorithm integrating multi-test results into a simplified risk score, designed to guide risk assessment, testing recommendations, and treatment eligibility within the BATWatch™ Protocol.

The BLI functions as a multi-stage decision engine, integrating biomarker results, genetic factors, and mechanism panel outcomes into a single score. It supports healthcare providers in determining appropriate next steps for testing and treatment.

Key Phases of the BLI Decision Engine:

a) Pre-Test Risk Score: Estimates patient risk based on clinical and genetic factors to guide testing urgency and insurance pre-authorization.
b) Active Testing Risk Score: Updates risk level based on BAT biomarker results to determine if further testing or treatment is needed.
c) Final Intervention Score: Guides treatment decisions by integrating BA and T test results to assess the severity of risk and the need for intervention.

2.5 BAT Test

Definition: A standardized classification for all validated blood-based Alzheimer’s biomarker tests that measure Beta-Amyloid and/or Tau proteins.

Purpose:
• Ensures consistent terminology across different diagnostic tests and providers.
• Simplifies complex biomarker test results for healthcare professionals and patients.
• Allows flexibility to incorporate multiple diagnostic options in the BATWatch Protocol.

2.6 BAT Testing

Definition: The process of biomarker assessment that measures BAT Levels using various blood-based diagnostic methodologies.

Purpose:
• Standardizes all validated blood-based BAT testing methods.
• Ensures a structured and repeatable approach to longitudinal biomarker monitoring.
• Provides a flexible framework to integrate new, emerging diagnostic technologies.

2.7 BAT Pill

Definition: The BAT Pill is an intervention that promotes autophagy-driven clearance of BAT Levels to support cognitive health.

Purpose:
• Targets BAT Levels with removal through enhanced autophagy.
• Supports long-term brain health and cognitive function preservation.
• Functions as the primary therapeutic component of the BATWatch Protocol.

2.8 BAT Pill Protocol

Definition: A structured treatment framework that outlines the dosage, timing, and monitoring of the BAT Pill intervention.

Purpose:
• Ensures that BAT Pill treatment is applied systematically and effectively.
• Helps healthcare providers personalize Alzheimer’s prevention strategies.
• Establishes a standardized monitoring process to track biomarker changes post-treatment.

2.9 BATophagy

Definition: BATophagy describes the targeted use of autophagy to facilitate the clearance of Beta-Amyloid and Tau proteins.

Purpose:
• Defines the biological mechanism underlying the BAT Pill Protocol.
• Explains how autophagy activation contributes to neuroprotection.
• Provides an intuitive way to communicate the scientific basis of Alzheimer’s prevention.

2.10 Trademarks

To ensure clarity and consistency in communication, certain terminology within these terms and conditions are designated with proprietary naming conventions, including “BATWatch,” “BAT Pill,” “BATophagy,” and related terminology. These terms are trademarked solely to standardize references across clinical protocols, provider education, and public awareness materials.

While the ™ symbol is used in external communications, it has been omitted in the body of these terms of service for readability. The use of these terms does not imply commercialization or product promotion but serves as a framework for structuring Alzheimer’s prevention and monitoring methodologies.